Skip to main content

Advertisement

SpringerLink
Log in

Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma

  • Clinical Study – Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Even after gross tumor resection and combined radiochemotherapy, glioblastomas recur within a few months. Salvage therapy often consists of rechallenging with temozolomide in a dose-intensified schedule. Previously, low-dose metronomic temozolomide in combination with cyclo-oxigenase 2 inhibitors has had a beneficial effect as first-line treatment for glioblastoma. We report our experience with this procedure in recurrent glioblastomas after standard treatment. From June 2007 to April 2009, 28 patients with recurrent glioblastoma received continuous low-dose temozolomide of 10 mg/m2 twice daily and 200 mg celecoxib. Before therapy the recurrent tumor was resected in 19 of 28 patients. Microvessel density (MVD) was determined by immunohistochemistry in 19 patients, and MGMT promoter methylation status, using the pyrosequencing method, was determined in 17 patients. In 14/28 patients, positron emission tomography with [F-18]-fluoroethyl)-l-tyrosine (FET-PET) was performed. Tumor progression was defined by the Macdonald criteria on MRI every 8–12 weeks or by clinical deterioration. The median time to progression was 4.2 months. Progression-free survival (PFS) after 6 months was 43%. Except for a lymphopenia in one patient, there was no grade 3 or 4 toxicity. PFS did not correlate with MVD or MGMT status. A high FET uptake correlated with tumor control after 6 months under therapy (P = 0.041, t-test). Low-dose continuous temozolomide in combination with celecoxib seems to have activity in recurrent glioblastoma without relevant toxicity. High FET uptake correlated with a better outcome under metronomic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  2. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361

    Article  CAS  PubMed  Google Scholar 

  3. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crino L, Ermani M (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155–1160

    Article  CAS  PubMed  Google Scholar 

  4. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    Article  CAS  PubMed  Google Scholar 

  5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886

    CAS  PubMed  Google Scholar 

  6. Albertsson P, Lennernas B, Norrby K (2006) On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A. Acta Oncol (Stockholm, Sweden) 45:144–155

    Article  CAS  Google Scholar 

  7. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P (2005) Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31–40

    Article  CAS  PubMed  Google Scholar 

  8. Tuettenberg J, Grobholz R, Seiz M, Brockmann MA, Lohr F, Wenz F, Vajkoczy P (2009) Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 135:1239–1244

    Article  CAS  PubMed  Google Scholar 

  9. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  CAS  PubMed  Google Scholar 

  10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    CAS  PubMed  Google Scholar 

  11. Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke M, Allgauer M, Schuierer G, Koch H, Schlaier J, Ulrich W, Brawanski A, Bogdahn U, Steinbrecher A (2003) Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 98:2678–2686

    Article  PubMed  Google Scholar 

  12. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115

    CAS  PubMed  Google Scholar 

  13. Chamberlain MC (2008) Pseudoprogression in glioblastoma. J Clin Oncol 26:4359; author reply 4359–4360

  14. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461

    Article  PubMed  Google Scholar 

  15. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K (2004) Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mole Imaging 31:1464–1470

    Article  Google Scholar 

  16. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neuro-oncol 91:329–336

    Article  CAS  Google Scholar 

  17. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    Article  CAS  PubMed  Google Scholar 

  18. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66:587–589

    Article  CAS  PubMed  Google Scholar 

  19. Koch D, Wick W (2006) Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. J Neurooncol 77:219–220

    Article  PubMed  Google Scholar 

  20. Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, Tonn JC, Hilt D, Westphal M (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360

    Article  PubMed  Google Scholar 

  21. Hau P, Kunz-Schughart L, Bogdahn U, Baumgart U, Hirschmann B, Weimann E, Muhleisen H, Ruemmele P, Steinbrecher A, Reichle A (2007) Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study. Oncology 73:21–25

    Article  CAS  PubMed  Google Scholar 

  22. Johansson M, Bergenheim AT, Widmark A, Henriksson R (1999) Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Br J Cancer 80:142–148

    Article  CAS  PubMed  Google Scholar 

  23. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S (2006) Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 37:272–282

    Article  PubMed  Google Scholar 

  24. Wiewrodt D, Nagel G, Dreimuller N, Hundsberger T, Perneczky A, Kaina B (2008) MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int J Cancer 122:1391–1399

    Article  CAS  PubMed  Google Scholar 

  25. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Re C (2010) Prognostic value of O(6)-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neuro-oncol 97:311–322

    Article  CAS  Google Scholar 

  26. Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, Katoh M, Murata J, Ozaki Y, Ito T, Fujimoto S, Kaneko S, Nagashima K, Tanaka S (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32:1220–1227

    Article  PubMed  Google Scholar 

  27. Lee SM, Thatcher N, Crowther D, Margison GP (1994) Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69:452–456

    CAS  PubMed  Google Scholar 

  28. Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro-oncology 11:69–79

    Article  CAS  PubMed  Google Scholar 

  29. Floeth FW, Sabel M, Stoffels G, Pauleit D, Hamacher K, Steiger HJ, Langen KJ (2008) Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions. J Nucl Med 49:730–737

    Article  PubMed  Google Scholar 

  30. Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, Jansen P, Coenen HH, Steiger HJ, Langen KJ (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519–527

    Article  CAS  PubMed  Google Scholar 

  31. Popperl G, Gotz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, Tatsch K (2006) Serial O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imag 33:792–800

    Article  Google Scholar 

  32. Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C (2008) Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol 88:205–210

    Article  CAS  PubMed  Google Scholar 

  33. Kurzen H, Schmitt S, Naher H, Mohler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14:515–522

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany

    Florian Stockhammer, Martin Misch, Marcus Czabanka & Peter Vajkoczy

  2. Department of Neuropathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany

    Arend Koch & Cristiane Blechschmidt

  3. Department of Nuclear-Medicine, Charité Universitätsmedizin Berlin, Schumannstr. 20/21, 10117, Berlin, Germany

    Michail Plotkin

  4. Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1–3, 68167, Mannheim, Germany

    Jochen Tuettenberg

Authors
  1. Florian Stockhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Misch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arend Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcus Czabanka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michail Plotkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cristiane Blechschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jochen Tuettenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peter Vajkoczy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Stockhammer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stockhammer, F., Misch, M., Koch, A. et al. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100, 407–415 (2010). https://doi.org/10.1007/s11060-010-0192-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0192-y

Keywords

Search

Navigation